Sign In
Buy MGTX
$9.39
+0.150 (+1.62%)
At Close: Jun 03, 2026
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:30am, Friday, 15'th May 2026
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 14'th May 2026
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Com
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
10:10am, Thursday, 14'th May 2026
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.51 per share a year ago.
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
08:00am, Thursday, 14'th May 2026
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostom
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
11:00am, Tuesday, 05'th May 2026
MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
07:55am, Monday, 20'th Apr 2026
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
MeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume on Analyst Upgrade
01:01am, Saturday, 18'th Apr 2026
MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) shares saw unusually-strong trading volume on Friday after Royal Bank Of Canada raised their price target on the stock from $16.00 to $24.00. Roy
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
10:16am, Thursday, 16'th Apr 2026
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
07:47am, Thursday, 16'th Apr 2026
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an und
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
07:10am, Thursday, 16'th Apr 2026
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered i
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced positive three-year d
MeiraGTx: Turning Dry Mouth Into Liquid Gold
01:26pm, Wednesday, 15'th Apr 2026
MeiraGTx is approaching a pivotal Phase 1 data readout for AAV-hAQP1 in radiation-induced xerostomia, with the stock recently hitting 52-week highs. MGTX's riboswitch-controlled gene therapy platform,
- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for b
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
10:21am, Tuesday, 31'st Mar 2026
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
